Meeting
2023 ASCO Annual Meeting
Phase 1 clinical trial results for NG-350A, a novel transgene-armed and tumor-selective vector: Differential effects of intravenous (IV) versus intratumoral (IT) dosing on immune pharmacodynamics (PD).
Authors
Minesh Patel
Akamis Bio, Abingdon, United Kingdom
Minesh Patel , Chris Cox , David Krige , Lyle Walker , Vladimir Evilevitch , Jo Carter , Matthew Thomas , Samantha Bucktrout , Brian Champion , Thomas Lillie , Lee S. Rosen , Aung Naing
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT03852511
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2572)
DOI
10.1200/JCO.2023.41.16_suppl.2572
Abstract #
2572
Poster Bd #
414
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors.
First Author: Iwona A. Lugowska
Poster
2023 ASCO Annual Meeting
A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.
First Author: Christine H. Chung
Poster
2023 ASCO Annual Meeting
Phase 1/1b study of PRGN-3005 autologous UltraCAR-T cells manufactured overnight for infusion next day to advanced stage platinum resistant ovarian cancer patients.
First Author: John B. Liao
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase I results of a phase I/II study of pembrolizumab and AR signaling inhibitor (ARSI) with 225Ac-J591.
First Author: Michael Philip Sun